Access the Endocrinology Newsmakers Dashboard (Free Excel) Drugmakers work on triple agonist therapies to treat diabetes, obesity Several drugmakers are working on triple agonist therapies that target multiple receptors, such as GLP-1, GIP and glucagon (GCG)
Biotin is generally well tolerated, but high levels can interfere with certain lab tests, including some thyroid and cardiac blood work
These data are consistent with one of two scenarios, either (1) direct peptide-stimulated inhibition of GLP-1R and Y1-R on -cells, or (2) indirect peptide-mediated insulin release leading to inhibition of glucagon release, as observed in previous studies 50,51
Mutations of SHANK2, SHANK3, NLGN4 , and NRXN1 are considered to cause ASD by altering synaptic connectivity and neuronal excitability, resulting in excitatory/inhibitory (E/I) imbalance (16)
Certain peptides are part of longer-term wellness or weight management plans, and stopping suddenly may affect results or symptom management
May be associated with inflammation
